Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372669 | 0.86 | EDNRA (0.57) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL8054308 | 0.86 | EDNRA (0.57) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL20565327 | 0.85 | NSD2 (0.57) | EDNRAKMT2A | |
| SCHEMBL6073527 | 0.84 | CASP6 (0.60) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL15461567 | 0.84 | EDNRA (0.54) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL23092875 | 0.84 | EDNRA (0.55) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL29900505 | 0.84 | EDNRA (0.55) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL3529089 | 0.83 | EDNRA (0.53) | EDNRAKMT2AMEN1RXFP1CASP6 | |
| SCHEMBL4446896 | 0.82 | CCR8 (0.64) | EDNRAKMT2AMEN1SLC40A1PKM | |
| SCHEMBL21387943 | 0.81 | RXFP1 (0.58) | EDNRAKMT2AMEN1RXFP1CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-2772480-B1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-7026475-B2 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20040122003-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20040116412-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1404340-A1 | NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100552-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-05-29 | — | — | US | disclosed |
| WO-2002100411-A1 | NAPHTOTHIAZINE POSITIVE ALLOSTERIC AMPA RECEPTOR MODULATORS (PAARM) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100552-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | GRM1, GRM2, GRIN1 | EDNRA 389/4885KMT2A 1246/4885MEN1 3254/4885 |
| US-20040122003-A1 | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions | GRM1, GRM2, GRIN1 | EDNRA 389/4885KMT2A 1246/4885MEN1 3254/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | EDNRA 1366/4885KMT2A 1254/4885MEN1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.